Skip to main content

Table 2 Diagnostic accuracy of combinations of serum sCD40L, CA19-9, and/or CEA to detect PDAC by logistic regression in the validation dataset

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Marker panel*

Cut-off point†

Sensitivity‡

Specificity

sCD40L

0.45

80.0%

85.5%

CA19-9

0.35

80.0%

72.7%

CEA

0.45

68.9%

60.0%

sCD40L + CA19-9

0.35

80.0%

89.1%

sCD40L + CEA

0.60

80.0%

85.5%

CA19-9 + CEA

0.41

80.0%

70.9%

sCD40L + CA19-9 + CEA

0.45

84.4%

90.9%

  1. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
  2. *Each marker is included as a linear term and evaluated as a panel from one to three markers combination.
  3. †Cut-off point refers to the probability cut-off point to classify subjects as having PDAC or non-PDAC in binary logistic regression.
  4. ‡For comparison among panels, the cut-off point ensures a target sensitivity of around 80%.